The Role of EGFR Inhibitor Therapy as Post-Operative Treatment for Early Stage NSCLC: A Controversial Question (audio)

GRACEcast Lung Cancer Audio

English - March 17, 2010 12:02 - 33 minutes - 31 MB - ★★★★★ - 1 rating
Science Health & Fitness Medicine grace cancergrace gracecast lung cancer nsclc chemotherapy chemo radiation non Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Expert Round Table with Drs. Anne Tsao and Alex Farivar: Case Discussion on Isolated Brain Metastasis (audio)

Next Episode: Individualizing First Line Therapy for Advanced NSCLC, by Dr. Suresh Ramalingam (audio)

Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as post-surgical treatment for advanced NSCLC.